UroGen (URGN): Bozor kapitallashuvining daromadga nisbati
Sotuvlar nisbatidagi narx baholovi FDA ning qat'iy talablari va patent himoyasining UroGen Pharma Ltd. (URGN) dinamikasiga ko'rsatgan ta'sirini yaqqol namoyish etadi, bunda 5.10 ushbu ko'rsatkichning joriy qiymati vazifasini o'taydi. Shifokorlarning urotelial terapiyaga bo'lgan yuqori ishonchi kompaniyaning innovator sifatidagi maqomini tasdiqlaydi, gidrogelning noyob xususiyati esa minimal ishlab chiqarish xarajatlari bilan global biznesni uzluksiz kengaytirish imkonini beradi.
UroGen Pharma (URGN) kompaniyasi koʻrsatkichlari kesimi va tahlili
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- birja kapitallashuvi ma'lumotlari:
- balans kapitallashuvi ko'rsatkichlari:
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Qarzning kapitalga nisbati UroGen Pharma Ltd.|URGN - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati ko'rsatkichi UroGen Pharma|URGN - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati UroGen Pharma|URGN - Kompaniyaning uzoq muddatli qarzi|Qisqa muddatli majburiyatlar UroGen Pharma|Oraliq qoplash koeffitsiyenti urogen.com
- foyda va multiplikatorlar bo'yicha ma'lumotlar:
URGN - Sof foyda|Prognoz qilingan kelajakdagi foyda UroGen Pharma Ltd.|URGN - Narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori UroGen Pharma Corp|URGN - Narxning foydaga va o‘sish sur’atiga nisbati|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati koeffitsiyenti UroGen Pharma Corp|URGN - EBITDA operatsion foydasi|Bir aksiya uchun sof foyda (EPS TTM) UroGen Pharma|URGN - So'nggi 12 oy davomida bir aksiya uchun sof foyda|So'nggi 12 oy davomida bitta aksiya uchun foydaning yillik o'sishi urogen.com|URGN - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun sof foyda o'sishi prognozi UroGen Pharma Ltd.
- emitentning tushumi va sotuvlari tafsilotlari:
Kompaniyaning jamlanma tahliliyoti:UroGen Pharma Ltd, URGN
P/S koeffitsiyenti biznesning bozor qiymatini uning daromadiga nisbatan aks ettiradi va bu aktivning adolatli qiymatini generatsiya qilingan savdolar prizmasi orqali baholash imkonini beradi. Median P/S tahlili UroGen Pharma Ltd. (URGN) kapitalizatsiyasini uning modernizatsiya qilingan onkologik dori ishlab chiqarish korxonalarining samaradorligi bilan solishtirishga yordam beradi hamda aksiya narxi joriy quvvatdan foydalanish va daromad o'sish sur'atlari bilan asoslangan yoki yo'qligini aniqlaydi.
UroGen Pharma Ltd. raqobatchilari
ONC - Sotuvga nisbatan narx|P/S multiplikatori HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Sotuvga nisbatan narx|ascentage.com - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati CGON (cgoncology.com)|BCAX: P/S multiplikatori|PSNL - Narx/daromad koeffitsiyenti|ERAS (Erasca Oncology) - P/S multiplikatori|P/S multiplikatori Delcath Systems, Inc.|Narxning daromadga nisbati ymabs.com (YMAB)|Narxning daromadga nisbati AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Kapitalizatsiyaning daromadga nisbati|Accuray Inc. (ARAY) - Sotuvga nisbatan narx|SELLAS Life Sciences Group, Inc. - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Narxning daromadga nisbati|HURA - Narx/daromad koeffitsiyenti|TARA (Protara Therapeutics, Inc.) - P/S multiplikatori|P/S multiplikatori Fate Therapeutics Inc|P/S multiplikatori WHWK|P/S multiplikatori TScan Therapeutics Inc (TCRX)|Narxning daromadga nisbati championsoncology.com CSBR|XBIT - Kapitalizatsiyaning daromadga nisbati|CVM - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati OSTX (OS Therapies)|RADX: P/S multiplikatori|Artiva Biotherapeutics Inc. - Bozor kapitallashuvining daromadga nisbati|ANL (Adlai Nortye) - P/S multiplikatori|P/S multiplikatori verupharma.com|Kapitalizatsiyaning daromadga nisbati TPST (tempesttx.com)|Kapitalizatsiyaning daromadga nisbati Xilio Therapeutics Inc XLO|P/S multiplikatori RENB (Enochian BioSciences)|Mural Bio - Narxning daromadga nisbati|KAPA - Narxning daromadga nisbati|OnKure Therapeutics (OKUR) - Kapitalizatsiyaning daromadga nisbati|GDTC: P/S multiplikatori|Sotuvga nisbatan narx Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Tharimmune Corp (THAR)|P/S multiplikatori ADVB|GNPX - Sotuvga nisbatan narx|Narxning daromadga nisbati calidibio.com CLDI|SBFM - Kapitalizatsiyaning daromadga nisbati|XBIO - Narxning daromadga nisbati|SLRX: Narxning daromadga nisbati|Purple Biotech (PPBT) - Narxning daromadga nisbati|AON - Bozor kapitallashuvining daromadga nisbati|Kapitalizatsiyaning daromadga nisbati BGNE|P/S multiplikatori Checkpoint Therapeutics Inc.|P/S multiplikatori ELEV|Kapitalizatsiyaning daromadga nisbati iCAD ICAD|P/S multiplikatori IKNA (Ikena Oncology, Inc.)|Bozor kapitallashuvining daromadga nisbati NTBL|Viracta Therapeutics, Inc. - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning daromadga nisbati Ascentage Pharma Group Ltd
